Article Text

other Versions

PDF
The Hong Kong Diastolic Heart Failure Study: a Randomized Control Trial of Diuretics, Irbesartan and Ramipril on Quality of Life, Exercise Capacity, Left Ventricular Global and Regional Function in Heart Failure With a Normal Ejection Fraction.
  1. Gabriel W K Yip (gabrielyip{at}cuhk.edu.hk)
  1. Chinese University of Hong Kong, Hong Kong
    1. Mei Wang
    1. The Chinese University of Hong Kong, Hong Kong
      1. Tian Wang
      1. The Chinese University of Hong Kong, Hong Kong
        1. Skiva Chan
        1. The Chinese University of Hong Kong, Hong Kong
          1. Jeffrey W H Fung
          1. The Chinese University of Hong Kong, Hong Kong
            1. Leata Yeung
            1. The Chinese University of Hong Kong, Hong Kong
              1. Thomas Yip
              1. Yan Chai Hospital, Hong Kong
                1. Suet T Lau
                1. Princess Margaret Hospital, Hong Kong
                  1. Chu P Lau
                  1. Hong Kong University, Hong Kong
                    1. Man O Tang
                    1. Hong Kong University, Hong Kong
                      1. Chuk M Yu
                      1. Chinese University of Hong Kong, Hong Kong
                        1. John E Sanderson (j.e.sanderson{at}bham.ac.uk)
                        1. University of Birmingham, United Kingdom

                          Abstract

                          Background Although heart failure with a preserved or normal ejection fraction (HFNEF or diastolic heart failure) is common, treatment outcomes on quality of life and cardiac function are lacking. We assessed the effect of renin-angiotensin blockade by irbesartan or rampril in combination with diuretics on quality of life (QoL), regional and global systolic and diastolic function in HFNEF patients.

                          Methods 150 patients with HFNEF (LVEF >45%) were randomized to (1) diuretics alone, (2) diuretics plus irbesartan, or (3) diuretics plus ramipril. QoL, 6-minute walk test (6MWT) and Doppler echocardiography were performed at baseline, 12, 24 and 52 weeks.

                          Resutls The QoL score improved similarly in all 3 groups by 52 weeks (-46%, 51%, and 50% respectively, all p<0.01), although 6MWT increased only slightly (average +3-6%). Recurrent hospitalization rates were equal in all groups (10-12% in 1 year). At 1 year, LV dimensions or LVEF were unchanged in any group, though both systolic and diastolic blood pressures were lowered in all three groups from 4 weeks onwards. At baseline both mean peak systolic (Sm) and early diastolic (Em) mitral annulus velocities were reduced and increased slightly in the diuretic plus irbesartan (Sm 4.5±0.17 to 4.9±0.16 cm/sec; Em 3.8±0,25 to 4.2±0.25 cm/sec) and ramipril (Sm 4.5±0.24 to 4.9±0.2 cm/sec; Em 3.3±0.25 to 4.04±0.32 cm/sec) groups (both p<0.05). NT-proBNP levels were raised at baseline (595±905; range 5-4748 pmol/l) and fell in the irbesartan (-124±302 pmol/l, p=0.01) and ramipril (-173±415, p=0.03) groups only.

                          Conclusions In this typically elderly group of HF patients with normal LVEF,diuretic therapy significantly improved symptoms and neither irbesartan nor ramipril had a significant additional effect. However, diuretics in combination with irbesartan or ramipril marginally improved LV systolic and diastolic longitudinal LV function, and lowered BNP over one year.

                          • angiotensin
                          • diastole
                          • heart failure
                          • treatment

                          Statistics from Altmetric.com

                          Request permissions

                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.